Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society
  • Primary citation Briand et al. 1984. Cancer Res. 44(3):1114-9. PMID: 6362856

Tool Details

  • Tool name: MCF7/S0.5 Cell Line
  • Alternate names: MCF7/S0.5; MCF-7/S0.5; MCF7 S0.5
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF7
  • Organism: Human
  • Donor: Female, 69 y.o., Caucasian
  • Tissue: Breast
  • Gender: Female
  • Cancer type: Breast cancer; Invasive breast carcinoma of no special type
  • Morphology: Epithelial; Adherent polygonal epithelia
  • Growth properties: Adherent
  • Model: Tumour line
  • CRISPR: No
  • Conditional: Yes
  • Receptors of note: Oestrogen receptor and progesterone receptors
  • Application: Hormone and anti-hormone effects studies; Studies of the effect of oestrogens; Estradiol and tamoxifen effects studies
  • Description: The MCF7/S0.5 human breast cancer cell line has been established to grow at low serum. The presence of hormones in the serum required in tissue culture media complicates the demonstration of specific hormone and antihormone effects. Methods to overcome this have included charcoal-treated serum and serum-free medium. However, both methods have serious drawbacks. Therefore, the MCF-7/S0.5 cell line has been adapted to long-term growth at 0.5 % fetal bovine serum in order to reduce the oestrogen supply via serum and to enable oestrogen receptor-mediated growth inhibition with the antiestrogen tamoxifen.
    The MCF7/S0.5 cells are also useful for studies of effect of oestrogens, if they, instead of 1 % fetal calf serum, are cultivated with 10% newborn calf serum which contains very low oestrogenic activity.
    MCF7/S0.5 cells expresse both oestrogen receptor and progesterone receptors.
    Many tamoxifen resistant cell lines have been derived from MCF7/S0.5 and utilized as a parental control to its derivative cell lines in parallel experiments
  • Research area: Cancer; Drug development
  • Production details: This MCF7 subline was established buy stepwise reduction in the serum concentration from 5% fetal calf serum to 0.5 % in growth medium consisting of DMEM: Ham's F-12 medium (1:1) supplemented with 2mM glutamine and insulin (6ng/ml)
  • Cellosaurus ID: CVCL_1D47

  • For Research Use Only

Target Details

  • Target: Oestrogen receptor

Application Details

  • Application: Hormone and anti-hormone effects studies; Studies of the effect of oestrogens; Estradiol and tamoxifen effects studies

Handling

  • Format: Frozen
  • Passage number: Passage 408 (AL2542, AL2543)
  • Growth medium: Phenol-red-free DMEM/F12 medium supplemented with 1% Fetal calf serum 2.5 mM Glutamax and 6 ng/ ml Insulin
  • Temperature: 37C
  • Atmosphere: 5% CO2
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1
  • Subculture routine: Split at 70-80% confluence: 1:3 to 1:6 (seeding at 2-4x104 cells/cm2) using 0.05% trypsin or trypsin or 0.05% trypsin/EDTA solution. Change the media every 2-3 days

Documentation

Related Tools

Product Image

H357 Cell Line

#153422
Product Image

MCF10A-EGFR1m-21 cell line

#161188
Product Image

MM165 cell line

#161627

References

  • •  Joshi et al. 2016. Oncotarget. :. PMID: 27528030
  • •  Alves et al. 2016. Clin Cancer Res. :. PMID: 27252418
  • •  Thomsen et al. 2015. Breast Cancer Res Treat. :. PMID: 26585578
  • •  Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755
  • •  Sonne-Hansen et al. 2005. J Steroid Biochem Mol Biol. 93(1):25-34. PMID: 15748829
  • •  Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159
  • •  Madsen et. al. 1995. Mol Cell Endocrinol 109(2):197-207. PMID: 7664983
  • •  Lykkesfeldt et al. 1994. Cancer Res. 54(6):1587-95. PMID: 8137264
  • •  Lykkesfeldt et al. 1989. Mol Cell Endocrinol. 62(2):287-96. PMID: 2744230
  • •  Lykkesfeldt et al. 1986. Br J Cancer. 53(1):29-35. PMID: 3947513
  • •  Briand et al. 1984. Cancer Res. 44(3):1114-9. PMID: 6362856